NasdaqGM:LGNDPharmaceuticals
Ligand Pharmaceuticals (LGND) Is Up 7.6% After Raising Long-Term Royalty Growth Outlook - What's Changed
Ligand Pharmaceuticals recently updated its long-term outlook, projecting 40% royalty revenue growth for 2026 and a 23% compound annual growth rate through 2030, supported by products including Filspari, Ohtuvayre and Capvaxive.
The company also highlighted more than US$1.00 billion in deployable capital for new royalty deals targeting unmet medical needs, underlining its capacity to expand the portfolio further.
We’ll now examine how this upgraded royalty growth outlook, underpinned by...